Drug Group Target Remarks References
Ketoprofen NSAID COX-1 >> COX-2 198
Aspirin NSAID COX-1 >> COX-2 186
Naproxen NSAID COX-1, COX-2 198
Ibuprofen NSAID COX-1, COX-2 198
Diclofenac NSAID COX-1, COX-2 185
Ketorolac NSAID COX-1, COX-2 199
Indomethacin NSAID COX-1, COX-2 200
Dipyrone (metamizole) NSAID COX-1, COX-2 201
Piroxicam NSAID COX-2 > COX-1 186
Meloxicam NSAID COX-2 >> COX-1 186
Nimesulide NSAID COX-2 >> COX-1 183
Celecoxib NSAID COX-2 >> >COX-1 183
Etoricoxib NSAID COX-2 >> >COX-1 183
Paracetamol (acetaminophen) Related to NSAIDs COX-1, COX-2-non-substrate mechanism 38,39
Montelukast LTRA CysLTR1 Additional immunomodulatory properties have been suggested 46
Zafirlukast LTRA CysLT1 46
Pranlukast LTRA CysLT1 46
Zileuton Leukotriene synthesis inhibitor 5-LOX 202
Fevipiprant Prostaglandin receptor antagonist DP2 Phase 3 clinical trials 203
Asapiprant Prostaglandin receptor antagonist DP1 Phase 2 clinical trials ClinicalTrials.gov Identifier: NCT04705597
Laropiprant Prostaglandin receptor antagonist DP1 Temporarily approved in Europe as a component of a hypolipidemic drug 204
Vidupiprant Prostaglandin receptor antagonist DP2 > DP1 Phase 2 clinical trials ClinicalTrials.gov Identifier: NCT01018550